Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AxogenMEX:AXGN 47 PS Ratio is 159.78 as of Aug. 23, 2026, which is 3051% above its 10-year median of 5.07. GuruFocus rates MEX:AXGN with a GF Score™ of 47/100 and a GF Value™ of MXN1,610.37 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Axogen ranks worse than 84.18% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Axogen's share price is MXN800.66.
Axogen's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN5.01. Hence, Axogen's PS Ratio for today is 159.78.
Warning Sign:
Axogen Inc stock PS Ratio (=10.05) is close to 5-year high of 10.05.
The historical rank and industry rank for Axogen's PS Ratio or its related term are showing as below:
MEX:AXGN'
s PS Ratio Range Over the Past 10 Years
Min: 1.05 Med: 5.07 Max: 26.91
Current: 10.05
During the past 13 years, Axogen's highest PS Ratio was 26.91. The lowest was 1.05. And the median was 5.07.
MEX:AXGN's PS Ratio is ranked worse than 84.18% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 2.97
vs MEX:AXGN: 10.05
Axogen's Revenue per Sharefor the
three
months ended in Jun. 2026 was MXN1.31.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was MXN5.01.
During the past 12 months, the average Revenue per Share Growth Rate of Axogen was 13.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 14.10% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 11.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 15.00% per year.
During the past 13 years, Axogen's highest 3-Year average Revenue per Share Growth Rate was 471.30% per year. The lowest was -74.30% per year. And the median was 8.70% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Axogen PS Ratio Related Terms
Axogen PS Ratio Historical Data
* Premium members only.
The historical data trend for Axogen's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Axogen's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Axogen PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Axogen's PS Ratio distribution charts can be found below:
* The bar in red indicates where Axogen's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Axogen's Share Price of today is MXN800.66. Axogen's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN5.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Axogen (MEX:AXGN) has a PS Ratio of 159.78 as of Aug. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Axogen and its competitors. This is 3051% above median its historical median of 5.07. Over the past decade, Axogen's PS Ratio has ranged from 1.05 to 26.91. According to the industry distribution chart, Axogen ranks #676 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 84.2%.
Is Axogen's PS Ratio too high?
Axogen's current PS Ratio of 159.78 is 3051% above median its 10-year median of 5.07. Over the past 10 years, this metric has ranged from a low of 1.05 to a high of 26.91. The Medical Devices & Instruments industry median PS Ratio is 2.97. Axogen's value of 159.78 is 5279.8% above this industry median. Based on the distribution chart, Axogen ranks #676 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Axogen has a GF Score™ of 47/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Axogen's PS Ratio compare to ?
According to the Medical Devices & Instruments industry distribution chart, Axogen ranks #676 out of 803 companies for PS Ratio. This places Axogen in the lower half of its industry. The industry median PS Ratio is 2.97. Axogen's value of 159.78 is 5279.8% above this benchmark. Historically, Axogen's own PS Ratio has ranged from 1.05 to 26.91 over the past decade. While the company's 10-year median is 5.07 vs. the industry median of 2.97, Axogen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.97, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Axogen's current PS Ratio of 159.78 is 5279.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Axogen and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Axogen's current PS Ratio is 159.78, which is 3051% above median its own 10-year median of 5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Axogen stock overvalued right now?
Based on GuruFocus' analysis, Axogen (MEX:AXGN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,610.37, compared to a current price of MXN800.66 — trading 50.3% below its estimated fair value. The current PS Ratio is 159.78, which is 3051% above median its 10-year median of 5.07 and 5279.8% above the Medical Devices & Instruments industry median of 2.97. Axogen's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Axogen (MEX:AXGN), the current PS Ratio is 159.78 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Axogen (MEX:AXGN) Overvalued in 2026?
Based on GuruFocus' analysis, Axogen stock appears to be undervalued.
The current stock price of MXN800.66 is trading 50.3% below its estimated GF Value™ of MXN1,610.37.
GuruFocus considers Axogen to be Significantly Undervalued.
Key valuation signals for MEX:AXGN:
PS Ratio: 159.78 (3051% above median its 10-year median of 5.07)
GF Value™: MXN1,610.37 vs. price of MXN800.66 (50.3% below fair value)
Industry Position: 5279.8% above the Medical Devices & Instruments median (#676 of 803)
No single metric tells the full story. See the MEX:AXGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, and several other countries.
47GF Score
Get the complete analysis for MEX:AXGN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXGN has been successfully added to your 
